Swan Capital’s Lifecore Biomedical LFCR Stock Holding History

Swan Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-80	Closed	-$589	–	532
2025 Q3	$589	Buy	+80	New	+$605	﹤0.01%	426

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Grizzlyrock Capital Chicago, Illinois $143M AUM 6.82% 1-Year Est. Return

Swan Capital's LFCR Position: Q4 2025 in Review

Swan Capital sold out of Lifecore Biomedical (LFCR) in Q4 2025, closing a stake of 80 shares — an estimated $589 sold.

Swan Capital first reported a position in LFCR in Q3 2025 and held it in 1 quarter. The position peaked at $589 in Q3 2025. 104 funds tracked by Wall St. Rank hold LFCR as of Q4 2025.

Swan Capital reported no remaining Lifecore Biomedical position as of Q4 2025 after selling out during the quarter.
Swan Capital sold 80 Lifecore Biomedical shares in Q4 2025, an estimated $589.
Swan Capital first reported a position in Lifecore Biomedical in Q3 2025 and held it in 1 quarter.
Swan Capital's Lifecore Biomedical position peaked at $589 in Q3 2025.
104 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2025.

Based on Swan Capital's 13F filing for Q4 2025, filed 12 Feb 2026.